| Assessment Status | NCPE Assessment Process Discontinued |
| HTA ID | 25032 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Pembrolizumab (Keytruda®) in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy. |
| Assessment Process | |
| Rapid review commissioned | 24/04/2025 |
| Rapid review completed | 21/05/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE | 11/06/2025 |
| Pre-submission consultation with Applicant | 06/08/2025 |
| Full submission received from Applicant | 09/06/2026 |
| Preliminary review sent to Applicant | 25/08/2026 |
| NCPE assessment re-commenced | 23/09/2026 |
HTA was deemed no longer required due to conclusion of decision making by HSE, 05 October 2026
Please see the HSE Pricing and Reimbursement Tracker for information on the reimbursement status of this drug.